Class / Patent application number | Description | Number of patent applications / Date published |
514800100 | Vascular endothelial growth factor (e.g., VEGF-A, VEGF-B, etc.) or derivative | 87 |
20100249025 | PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR - The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity. | 09-30-2010 |
20100305034 | GROWTH FACTOR ISOFORM - An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ.ID NO.1, or variants thereof. | 12-02-2010 |
20100331250 | ANTI-ANGIOGENESIS FUSION PROTEINS - The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth. | 12-30-2010 |
20100331251 | POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 12-30-2010 |
20110003745 | GRANULATE-MATRIX - Composition comprising a granulate selected from the group consisting of autogenous bone material, bone/bone like material from natural sources, synthetic materials and mixtures thereof and a matrix obtainable by a self selective reaction of at least two precursors A and B in the presence of water. A kit for preparing said composition is also described. | 01-06-2011 |
20110009316 | PROTEOLYSIS RESISTANT ACTIVE VEGF - The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds. | 01-13-2011 |
20110034383 | CXCL12 GAMMA A CHEMOKINE AND USES THEREOF - Fragments of CXCL12 Gamma A chemokine having improved chemotaxis activity in vivo defined by an unprecedented capacity to associate and immobilise on extracellular glycans. | 02-10-2011 |
20110039772 | NOVEL USES OF VEGFXXXB - The invention provides VEGF | 02-17-2011 |
20110059890 | EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 03-10-2011 |
20110065636 | Screening and Therapy for Lymphatic Disorders Involving the FLT4 Receptor Tyrosine Kinase (VEGFR-3) - The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects. | 03-17-2011 |
20110144013 | VEGF-D Mutants and Their Use - The present invention is a VEGF-D protein, containing one or more amino acid mutations at the dimer interface, and their use in therapy, particularly in the promotion of angiogenesis. | 06-16-2011 |
20110207664 | Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins - The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors. | 08-25-2011 |
20110230405 | Peptides and Supported Peptides for Treating Skin Diseases - The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein is BBI. | 09-22-2011 |
20110275565 | BIOCOMPATIBLE POLYSACCHARIDE-BASED HYDROGELS - Modified polysaccharides and crosslinked modified polysaccharide compositions are described. Methods of using the crosslinked modified polysaccharide compositions to deliver proteins, oligonucleotides, or pharmaceutical agents are also disclosed. | 11-10-2011 |
20110281799 | Vascular Endothelial Growth Factor D (VEGF-D) Antibodies and Vectors, and Methods of Uses - VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications. | 11-17-2011 |
20110288020 | Use of VEGF and homologues to treat neuron disorders - The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGF | 11-24-2011 |
20110319327 | Polypeptides Homologous to VEGF and BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 12-29-2011 |
20120010138 | NOVEL USES OF VEGFXXXB - The invention provides VEGF | 01-12-2012 |
20120010139 | THERMAL RESPONSIVE COMPOSITION FOR TREATING BONE DISEASES - Thermal responsive compositions for treating bone diseases are provided. The thermal responsive composition for treating bone diseases includes a bone growth factor and a biodegradable copolymer. The biodegradable copolymer has a structure of Formula (I) or Formula (II): | 01-12-2012 |
20120058943 | Bioactive Hydrogel - The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds. | 03-08-2012 |
20120065129 | METHOD OF MASS PRODUCING GROWTH FACTOR USING ADIPOSE DERIVED ADULT STEM CELLS - The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics. | 03-15-2012 |
20120071405 | COMPOSITION OF INHIBITING PATHOLOGICAL ANGIOGENESIS - The present invention provides a pharmaceutical composition for inhibiting pathologic angiogenesis and/or cell proliferative disorder. The pharmaceutical composition of the present invention comprises an effective amount of LECT2 protein or analogue thereof, and a pharmaceutically acceptable carrier. | 03-22-2012 |
20120071406 | MODIFIED VEGF-A WITH IMPROVED ANGIOGENIC PROPERTIES - The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-2 ligand. The chimeric molecules of the present invention retain VEGFR-2 binding activity and an enhanced angiogenic activity as compared to native VEGF-A. | 03-22-2012 |
20120077741 | Treatment of Central Nervous System Disorders - The invention relates generally to methods of influencing central nervous system cells to produce progeny useful in the treatment of CNS disorders. More specifically, the invention includes methods of exposing a patient suffering from such a disorder to a reagent that modulates the proliferation, migration, differentiation and survival of central nervous system cells. These methods are useful for reducing at least one symptom of the disorder. | 03-29-2012 |
20120077742 | Expression System Of NELL Peptide - Recombinant NELL peptides and methods of preparing the same are disclosed. | 03-29-2012 |
20120101035 | VEGF Antagonist Formulations - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 04-26-2012 |
20120101036 | Novel cellular factor-containing solution compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 04-26-2012 |
20120115780 | Porogen Containing Calcium Phosphate Cement Compositions - Porogen containing calcium phosphate cement compositions are provided. Aspects of the cement compositions include a dry calcium phosphate reactant component, a setting fluid component and a porogen component. The porogen component includes at least first and second porogens having different pore forming profiles. Aspects of the invention include combining the cement components to produce a settable composition. Aspects of the invention further include the settable compositions themselves as well as kits for preparing the same. Methods and compositions as described herein find use in a variety of applications, including hard tissue repair applications. | 05-10-2012 |
20120157381 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR - The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions. | 06-21-2012 |
20120178682 | GB1 Peptidic Compounds and Methods for Making and Using the Same - GB1 peptidic compounds that specifically bind to a target molecule are provided. Also provided are methods for making and using the compounds. These compounds and methods find use in a variety of applications in which specific binding to target molecules, e.g., target proteins, is desired. | 07-12-2012 |
20120178683 | VEGF ANTAGONIST FORMULATIONS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 07-12-2012 |
20120225815 | Novel Cellular Factor-Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 09-06-2012 |
20120232008 | PLGF-1 IN HOMODIMERIC FORM - The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it. | 09-13-2012 |
20120238495 | Novel Cellular Factor-Containing Solution Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 09-20-2012 |
20120258915 | Proteolysis Resistant Active VEGF - The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds. | 10-11-2012 |
20120270781 | Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases. | 10-25-2012 |
20120283184 | INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS - The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides. | 11-08-2012 |
20120316110 | Injectable Cross-Linked Polymeric Preparations and Uses Thereof - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue. | 12-13-2012 |
20120322731 | NOVEL CYTOKINE CONTAINING COMPOSITIONS - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 12-20-2012 |
20130012435 | MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS - The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 01-10-2013 |
20130017996 | MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME - The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein. | 01-17-2013 |
20130029909 | TREATMENT OF CANCER - Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101. | 01-31-2013 |
20130040880 | Novel Cytokine Containing Compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 02-14-2013 |
20130045918 | Methods for Treating Diabetic Wounds - The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment. | 02-21-2013 |
20130065829 | PEPTIDES AND SUPPORTED PEPTIDES FOR TREATING SKIN DISEASES - The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein is BBI. | 03-14-2013 |
20130102531 | FUNCTIONAL VASCULARIZATION WITH BIOCOMPATIBLE POLYSACCHARIDE-BASED HYDROGELS - Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved. | 04-25-2013 |
20130143807 | Concentrated Protein Preparations of Bone Morphogenetic Proteins and Methods of Use Thereof - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 06-06-2013 |
20130172252 | Methods for promoting hair growth - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 07-04-2013 |
20130178418 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 07-11-2013 |
20130184205 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 07-18-2013 |
20130190235 | FUSION PROTEIN FOR ANTAGONIZING ANGIOGENESIS INDUCIBLE FACTORS AND USES THEREOF - The present invention relates to angiogenesis-inhibitory fusion proteins and use thereof. Particularly, the present invention provides fusion proteins inhibiting a plurality of angiogenic factors. More particularly, the present invention relates to the fusion proteins of VEGF receptor and FGF receptor and their applications in the treatment of angiogenesis related diseases. | 07-25-2013 |
20130261055 | Novel N- and C- terminal substituted antagonistic analogs of GH-RH - There is provided a novel series of synthetic analogs of hGH-RH(1-29)NH | 10-03-2013 |
20130261056 | VEGF ANTAGONIST FORMULATIONS - Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4. | 10-03-2013 |
20130274189 | VEGF Antagonist Formulations for Intravitreal Administration - Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4. | 10-17-2013 |
20130281369 | METHODS FOR STIMULATING HAIR GROWTH - A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human. | 10-24-2013 |
20130281370 | ANGIOGENESIS PROMOTED BY CAGED GROWTH FACTORS - The present disclosure relates to controlling the release of growth factors for the promotion of angiogenesis. The growth factors or a polymer matrix are modified by photoactive compounds, such that the growth factors are not released into an active form until they are irradiated with light. The disclosure also relates to tissue engineering scaffolds comprising one or more polymers and at least two growth factors. | 10-24-2013 |
20130288963 | ANTICANCER FUSION PROTEIN - A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an anti-angiogenic effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases. | 10-31-2013 |
20130296238 | METHOD OF TREATING AMD IN PATIENTS REFRACTORY TO ANTI-VEGF THERAPY - Disclosed herein are methods for the treatment of a patient having an ocular conditions such as age-related macular degeneration or diabetic macular edema through administration of a recombinant binding protein comprising an ankyrin repeat domain. In some embodiments, the composition may be administered every 8 weeks to every 16 weeks. In some embodiments, the patient being treated may be refractory to existing anti-VEGF therapies. | 11-07-2013 |
20130324465 | VEGF ANTAGONIST COMPOSITIONS AND USES THEREOF - The invention provides compositions and methods for treating a disease or disorder associated with vascular endothelial growth factor (VEGF). Specifically, the invention relates to an oligomerized VEGF binding domain to provide VEGF antagonism, and thereby treat diseases associated thereof. | 12-05-2013 |
20140100159 | USE OF RELAXIN TO RESTORE MATERNAL PHYSIOLOGY IN PREGNANCIES CONVEIVED BY ASSISTED REPRODUCTIVE TECHNOLOGIES - The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity. | 04-10-2014 |
20140100160 | NOVEL USE OF C-TERMINAL DOMAIN OF IGFBP-5 COMPRISING HEPARIN-BINDING DOMAIN AS AN ANGIOGENESIS INHIBITOR - The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector. | 04-10-2014 |
20140121160 | Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy - An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a PI-peptide. | 05-01-2014 |
20140135264 | COMPOUNDS AND METHODS OF MODULATING ANGIOGENESIS - A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of α | 05-15-2014 |
20140148386 | Method for prevention or treatment of diabetic vascular leakage-induced disease using C-peptide - Disclosed is a method for the prevention or treatment of vascular leakage-induced diseases and diabetic retinopathy, using C-peptide. Found to prevent extravascular leakage by inhibiting VEGF-induced disassembly of VE-cadherin, C-peptide can be applied to the prevention or treatment of various diabetic complications accompanied by vascular leakage. | 05-29-2014 |
20140179601 | FGF-9 AND ITS USE RELATING TO BLOOD VESSELS - There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis. | 06-26-2014 |
20140256630 | VEGF-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING - The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents. | 09-11-2014 |
20140315803 | METHODS FOR STIMULATING HAIR GROWTH - A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human. | 10-23-2014 |
20140315804 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF - The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided. | 10-23-2014 |
20140349929 | MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS - The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 11-27-2014 |
20150025007 | Methods to reduce scarring - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 01-22-2015 |
20150051147 | Methods for treating hidradenitis suppurativa - The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 02-19-2015 |
20150080299 | CONCENTRATED PROTEIN PREPARATIONS OF BONE MORPHOGENETIC PROTEINS AND METHODS OF USE THEREOF - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 03-19-2015 |
20150126446 | VASCULAR ENDOTHELIAL GROWTH FACTOR ANTAGONISTS AND METHODS FOR THEIR USE - The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis. | 05-07-2015 |
20150328251 | Glycosaminoglycans - Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue. | 11-19-2015 |
20150359842 | PRO-ANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF - Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof. | 12-17-2015 |
20150368302 | DESIGNED ANKYRIN REPEAT PROTEINS BINDING TO PLATELET-DERIVED GROWTH FACTOR - New designed ankyrin repeat proteins with binding specificity for PDGF-BB are described, as well as nucleic acids encoding such PDGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases. | 12-24-2015 |
20150368309 | PLACENTA GROWTH FACTOR IN TREATING DUCHENNE MUSCULAR DYSTROPHY - The present invention provides, among other things, methods and compositions for treating muscular dystrophy, in particular, Duchenne muscular dystrophy (DMD). In some embodiments, a method according to the present invention includes administering to an individual who is suffering from or susceptible to DMD an effective amount of a recombinant PLGF protein such that at least one symptom or feature of DMD is reduced in intensity, severity, or frequency, or has delayed onset. The present invention also provides exemplary recombinant PLGF proteins including monomeric, dimeric and single-chain PLGF proteins. | 12-24-2015 |
20160000873 | AGENTS WHICH INDUCE LYMPHANGIOGENESIS FOR USE IN THE TREATMENT OF CYSTIC KIDNEY DISEASE - The invention relates to methods and materials for treating a renal cystic disease in a subject suffering therefrom, the methods comprising administering the compound to the subject, wherein the compound is a lymphangiogenic agent such as an agonist of VEGFR-3, or a nucleic acid encoding said agent. | 01-07-2016 |
20160022775 | TREATING LYSOSOMAL STORAGE DISEASE - Provided herein are compositions, kits and methods related to the treatment of one or more lysosomal storage diseases (LSDs) in a subject and methods of identifying agents that are useful for the treatment of one or more LSDs. The compositions, kits, and methods are based on the novel discovery that agents effective for treating LSD must have two characteristics: they must inhibit cell death and reduce suppression of cell division caused by toxic substances that accumulate in LSD. Exemplary agents include polypeptides (e.g., IGF-1, VEGF) and small molecules (e.g., chlorotrianisene, clofoctal, colforsin, and tulobuterol). | 01-28-2016 |
20160033484 | SERUM-BASED, DIAGNOSTIC, BIOLOGICAL ASSAY TO PREDICT PREGNANCY DISORDERS - The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and/or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in contrast to normal pregnancy serum samples. Based on these distinctions, the assays are employed to predict pregnancy outcomes as early as first trimester. | 02-04-2016 |
20160067283 | COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR - The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions. | 03-10-2016 |
20160074481 | Clottable Concentrate Of Platelet Growth Factors And Preparation Method Thereof - The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGT-β, IGF, EGF, CTGF, bFGF and VEGF. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present disclosure also relates to a method for preparing a clottable concentrate of platelet growth factors including the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating the platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2° C. to 50° C., preferably within the range of from 25° C. to 45° C., and removing the solvent and/or the detergent by oil extraction and/or chromatographic means. | 03-17-2016 |
20160082154 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions and articles comprising mesothelial tissue and a growth factor, for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles induce modulated healing, including modulation of inflammation and induced neovascularization, when administered to damaged biological tissue. | 03-24-2016 |
20160151450 | Compositions and Methods for Treating Neuropsychiatric Disorders Using an Endothelin-B Receptor Agonist | 06-02-2016 |
20160158410 | POLYSACCHARIDE HYDROGELS FOR INJECTION WITH TUNABLE PROPERTIES - Injectable hydrogels comprising polysaccharides based on disaccharides the backbones of which form an α-helix structure and in which in at least 10% of the disaccharide units the primary hydroxyl groups are oxidized. | 06-09-2016 |
20160193298 | THERAPEUTIC USE OF VEGF-C AND CCBE1 | 07-07-2016 |
20220135651 | A MEMBRANE-BOUND FIT-1 DECOY AND USES THEREOF - We describe a Flt-1 decoy comprising a VEGF binding domain of Flt-1 and a membrane anchoring domain, in which the Flt-1 decoy does not substantially comprise an intracellular domain. | 05-05-2022 |